← Back to Screener
GRI Bio, Inc. Common Stock (GRI)
Price$2.51
Favorite Metrics
Price vs S&P 500 (26W)-103.85%
Price vs S&P 500 (4W)-1.44%
Market Capitalization$3.68M
All Metrics
Book Value / Share (Quarterly)$12.07
P/TBV (Annual)1.04x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-20.47
Price vs S&P 500 (YTD)-67.24%
EPS (TTM)$-91.65
10-Day Avg Trading Volume0.30M
EPS Excl Extra (TTM)$-91.65
EPS (Annual)$-45.61
ROI (Annual)-203.62%
Cash / Share (Quarterly)$16.53
ROA (Last FY)-143.06%
EBITD / Share (TTM)$-53.30
ROE (5Y Avg)-1160.96%
Cash Flow / Share (Annual)$-20.47
P/B Ratio0.61x
P/B Ratio (Quarterly)0.24x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-5.86x
ROA (TTM)-206.45%
EPS Incl Extra (Annual)$-45.61
Current Ratio (Annual)3.25x
Quick Ratio (Quarterly)3.11x
3-Month Avg Trading Volume0.31M
52-Week Price Return-94.05%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.75
P/S Ratio (Annual)36.85x
Asset Turnover (Annual)0.10x
52-Week High$80.36
EPS Excl Extra (Annual)$-45.61
CapEx CAGR (5Y)8.45%
26-Week Price Return-95.10%
Quick Ratio (Annual)3.11x
13-Week Price Return-61.71%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.25x
Enterprise Value$-4.544
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4822.00%
Cash / Share (Annual)$16.53
3-Month Return Std Dev106.08%
Net Income / Employee (TTM)$-3
ROE (Last FY)-203.62%
Net Interest Coverage (Annual)-4.10x
EPS Basic Excl Extra (Annual)$-45.61
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-91.65
ROI (TTM)-381.74%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.21
Price vs S&P 500 (52W)-129.14%
Year-to-Date Return-63.10%
5-Day Price Return6.25%
EPS Normalized (Annual)$-45.61
ROA (5Y Avg)-273.96%
Net Profit Margin (Annual)-4822.00%
Month-to-Date Return11.35%
Cash Flow / Share (TTM)$-5.59
EBITD / Share (Annual)$-45.59
Operating Margin (Annual)-4788.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-1158.00%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-91.65
P/TBV (Quarterly)1.09x
P/B Ratio (Annual)0.24x
Book Value / Share (Annual)$12.07
Price vs S&P 500 (13W)-64.58%
Beta-1.14x
Revenue / Share (TTM)$0.00
ROE (TTM)-381.74%
52-Week Low$2.10
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GRIGRI Bio, Inc. Common Stock | — | — | — | — | $2.51 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
GRI Bio is a clinical-stage biotech company developing immunomodulatory therapies for inflammatory, fibrotic, and autoimmune disorders. Its lead program, GRI-0621, is a RAR-beta/gamma dual agonist that modulates immune T cell responses, with an oral tazarotene formulation also in development. The company's pipeline includes GRI-0803, a Type 2 NKT cell agonist designed to treat autoimmune conditions.